Recent Advances in Chronic Lymphocytic Leukemia

REFERENCES

• Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med. 1990; 113: 525–539, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Brien S., del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307–318, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ghia P., Prato G., Scielzo C., Stella S., Geuna M., et al. Monoclonal CD5+ and CD5− B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004; 103: 2337–2342, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Catovsky D., Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin. Hematol. 1999; 36: 148–154, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Binet J. L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48: 198–206, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Montserrat E., Sanchez-Bisono J., Vinolas N., Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Molica S., Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712–2716, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Faderl S., Keating M. J., Do K. A., et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002; 16: 1045–1052, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Spati B., Child J. A., Kerruish S. M., Cooper E. H. Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study. Acta Haematol 1980; 64: 79–86, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Molica S., Levato D., Cascavilla N., Levato L., Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999; 62: 117–122, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Damle R. N., Wasil T., Fais F., et al. Ig Vgene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jelinek D. F., Tschumper R. C., Geyer S. M., et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 854–861, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Del Poeta G., Maurillo L., Venditti A., et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633–2639, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ghia P., Guida G., Stella S., et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262–1269, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hamblin T. J., Davis Z., Gardiner A., Oscier D. G., Stevenson F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lin K., Sherrington P. D., Dennis M., Matrai Z., Cawley J. C., Pettitt A. R. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404–1409, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Krober A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., Dohner H., Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wiestner A., Rosenwald A., Barry T. S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 2000; 343: 1910–1916, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Thornton P. D., Gruszka-Westwood A. M., Hamoudi R. A., et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol. J. 2004; 5: 47–54, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Cheson B. D., Bennett J. M., Grever M., Kay N., Keating M. J., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Estey E., Kantarjian H., Koller C., O'Brien S., et al. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 1994; 8: 2047–2051, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Raphael B., Andersen J. W., Silber R., et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine,and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J. Clin. Oncol. 1991; 9: 770–776, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Redman J. R., Cabanillas F., Velasquez W. S., McLaughlin P., Hagemeister F. B., et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rai K. R., Peterson B. L., Appelbaum F. R., Kolitz J., Elias L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J Med. 2000; 343: 1750–1757, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Keating MJ., O'Brien S., Lerner S., Koller C., Beran M., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Brien S. M., Kantarjian H. M., Cortes J., Beran M., Koller C. A., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Clin. Oncol. 2001; 19: 1414–1420, [CSA]
   Web of Science ®Google Scholar
• Hallek M., Schmitt B., Wilhelm M., et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German C LL Study Group. Br. J. Haematol. 2001; 114: 342–348, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Johnson S. A., Catovsky D., Child J. A., Newland A. C., Milligan D. W., Janmohamed R. Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs 1998; 16: 155–160, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ho A. D., Thaler J., Stryckmans P., et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J. Natl. Cancer Inst. 1990; 82: 1416–1420, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weiss M. A., Maslak P. G., Jurcic J. G., et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2003; 21: 1278–1284, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Waselenko J. K., Grever M. R., Beer M., Lucas M. A., Byrd J. C. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Semin. Oncol. 2000; 27(2 Suppl 5)44–51, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Robak T., Blonski J. Z., Kasznicki M., et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723–2729, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Robak T., Blonski J. Z., Kasznicki M., et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol. J. 2002; 3: 244–250, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Montillo M., Tedeschi A., O'Brien S., Raimondo F. D., Lerner S., et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114–120, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R. H., Kosty M., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1995; 13: 570–574, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lindemalm S., Liliemark J., Gruber A., Eriksson S., Karlsson M. O., Wang Y., Albertioni F. Comparison of cytotoxicity of 2-chloro- 2′-arabino-fluoro-2′-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica 2003; 88: 324–332, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Keating M., O'Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000, 6 Suppl 12: 86–90, [CSA]
   PubMed Web of Science ®Google Scholar
• O'Brien S. M., Kantarjian H., Thomas D., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 2001; 19: 2165–2170, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Peterson B. L., Morrison V. A., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lamanna N., Weiss M. A., Maslak P. G., Gencarelli A. N., Scheinberg D. A. Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL). Proc. Am. Soc. Clin. Oncol. 2003, Abstract 2333[CSA]
   PubMedGoogle Scholar
• Weiss M. A., Lamanna N., Maslak P. G., et al. Pentostatin, cyclophosphamide and rituximab (PCR therapy): A new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 2003, Abstract 2334[CSA]
   Web of Science ®Google Scholar
• Schulz H., Klein S. K., Rehwald U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and Fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115–3120, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Rai K. R., Peterson B. L., et al. The Addition of Rituximab to Fludarabine Significantly Improves Progression-Free and Overall Survival in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Proc. Am. Soc. Hem. Abstract 2003; 245, [CSA]
   Google Scholar
• Keating M. J., O'brien S., Albitar M., et al. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. J Clin Oncol. 2005, Mar 14 [Epub ahead of print][CSA]
   Web of Science ®Google Scholar
• Wierda W., O'brien S., Wen S., et al. Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2005, Mar 14; [Epub ahead of print][CSA]
   Web of Science ®Google Scholar
• Moreton P., Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin. Oncol. 2003; 30: 493–501, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Brien S. M., Kantarjian H. M., Thomas D. A., Cortes J., Giles F. J., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–2663, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lozanski G., Heerema N. A., Flinn I. W., et al. Alemtuzumab is an Effective Therapy for Chronic Lymphocytic Leukemia with p53 Mutations and Deletions. Blood 2004; 103: 3278–328, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Faderl S., Thomas D. A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2004; 101: 3413–3415, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• Weirda W., Faderl S., O'Brien S., et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed / refractory patients with CLL. Blood 2004; 104: 101a, (abstract 340)[CSA]
   Web of Science ®Google Scholar
• Hale G., Rebello P., Brettman L. R., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Frankel A. E., Fleming D. R., Hall P. D., et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003; 9: 3555–3561, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Khouri I. F., Keating M. J., Saliba R. M., Champlin R. E. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002; 4: 217–221, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Giralt S., Estey E., Albitar M., van Besien K., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004; 104: 2600–2602, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rondon G., Giralt S., Huh Y., Khouri I., Andersson B., et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669–672, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Milligan D. W., Fernandes S., Dasgupta R., et al. Autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses. Results of the MRC Pilot Study. Blood 2005; 105: 397–404, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Altes A., Sierra J., Esteve J., et al. CD34+-enriched CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol 2002; 30: 824–830, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Trneny M., Salkova J., Karban J., et al. Combined Therapeutic Modality with Rituximab, Fludarabine and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Transplantation (ASCT) Leads to Excellent Response Rate and High Probability of Molecular Remission in Chronic Lymphocytic Leukemia (CLL) Patients. 2002, Proceedings of American Society of Hematology Abstract 3176
   Google Scholar
• Tournilhac O., Cazin B., Lepretre S., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–365, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• F., Ferrer A., Lopez-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–984, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R. H., Kosty M., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin Oncol. 1995; 13: 570–574, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Peterson B., Piro L., Saven A., Vardiman J. W., et al. Phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003; 17: 323–327, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Khouri I. F., Saliba R. M., Giralt S. A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P., Da Prada G. A., Giorgiani G., et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409–2415, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Carella A. M., Cavaliere M., Lerma E., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Clin. Oncol. 2000; 18: 3918–3924, [CSA]
   Web of Science ®Google Scholar
• Liu D., Sieter K., Ciao J. W. MAP Regimen: A Novel Non-Myeloablative Conditioning Regimen of Mitoxantrone, Ara-C, and pentostatin (MAP Regimen) for Hematological Malignancies. 2002, Proceedings of American Society of Hematology, poster #2451
   Google Scholar
• Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J. Clin. Oncol. 2003; 21: 2747–2753, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Corradini P., Tarella C., Olivieri A., et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75–82, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McSweeney P. A., Niederwieser D., Shizuru J. A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–400, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar